Q4 2025 EPS Estimates for Legend Biotech Co. Decreased by Analyst (NASDAQ:LEGN)

Legend Biotech Co. (NASDAQ:LEGN) – Equities research analysts at HC Wainwright dropped their Q4 2025 earnings per share estimates for Legend Biotech in a research note issued on Friday, May 24th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of $0.10 for the quarter, down from their previous forecast of $0.16. HC Wainwright currently has a “Buy” rating and a $73.00 target price on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.84) per share.

A number of other equities analysts also recently commented on LEGN. Raymond James assumed coverage on Legend Biotech in a research report on Wednesday, March 13th. They set an “outperform” rating and a $86.00 price objective on the stock. Deutsche Bank Aktiengesellschaft began coverage on Legend Biotech in a research report on Thursday. They set a “buy” rating and a $60.00 price objective on the stock. Royal Bank of Canada lifted their target price on Legend Biotech from $85.00 to $86.00 and gave the company an “outperform” rating in a research report on Tuesday, May 14th. UBS Group lifted their target price on Legend Biotech from $76.00 to $81.00 and gave the company a “buy” rating in a research report on Monday, March 18th. Finally, Scotiabank upgraded Legend Biotech from a “sector perform” rating to a “sector outperform” rating and set a $65.00 target price on the stock in a research report on Wednesday, April 17th. Eleven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $81.10.

Legend Biotech Stock Performance

Shares of Legend Biotech stock opened at $41.41 on Monday. Legend Biotech has a one year low of $39.13 and a one year high of $77.32. The company has a market cap of $7.55 billion, a price-to-earnings ratio of -31.85 and a beta of 0.12. The company has a debt-to-equity ratio of 0.25, a quick ratio of 5.57 and a current ratio of 5.66. The business’s 50 day moving average price is $50.00 and its 200 day moving average price is $56.99.

Legend Biotech (NASDAQ:LEGN) last released its earnings results on Monday, May 13th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.13. Legend Biotech had a negative return on equity of 27.91% and a negative net margin of 135.92%. The business had revenue of $93.90 million for the quarter, compared to the consensus estimate of $143.24 million. During the same quarter last year, the business posted ($0.40) earnings per share. The business’s quarterly revenue was up 158.7% compared to the same quarter last year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Massachusetts Financial Services Co. MA grew its stake in Legend Biotech by 6.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,984,826 shares of the company’s stock worth $119,427,000 after purchasing an additional 117,794 shares in the last quarter. TimesSquare Capital Management LLC grew its stake in Legend Biotech by 15.4% during the 4th quarter. TimesSquare Capital Management LLC now owns 1,065,889 shares of the company’s stock worth $64,135,000 after purchasing an additional 142,118 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its stake in Legend Biotech by 15.9% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 163,130 shares of the company’s stock worth $9,816,000 after purchasing an additional 22,376 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in Legend Biotech by 101.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,708,510 shares of the company’s stock worth $114,761,000 after buying an additional 860,410 shares during the last quarter. Finally, Westfield Capital Management Co. LP lifted its holdings in Legend Biotech by 71.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,668,150 shares of the company’s stock worth $112,050,000 after buying an additional 696,096 shares during the last quarter. 70.89% of the stock is owned by institutional investors and hedge funds.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).